EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study

Cheoklong Ng, Taile Jing, Shicheng Yu, Jianjun Ye, Shun Zhang, Zhankui Jia, Qi Tang, Xiaoyi Hu, Minfeng Chen, Weiping Huang, Jitao Wu, Hai Bi und 16 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04154-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Cheoklong Ng und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Commission of Shanghai Municipality, Shanghai Municipal Health Commission, Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Disitamab vedotin (DV, RC48-ADC) has shown promising efficacy and manageable safety as monotherapy or combined with immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) patients progressing after systemic chemotherapy. This study evaluates the efficacy and safety of RC48-ADC plus ICIs in metastatic upper tract urothelial carcinoma (mUTUC) in a real-world setting.

Methods

This retrospective, multicenter study included 198 mUTUC patients treated with RC48-ADC plus ICI at 23 clinical centers between June 2021 and December 2023. Data were analyzed from July to September 2024. Primary endpoint: objective response rate (ORR). Secondary endpoints: progression-free survival (PFS), overall survival (OS), duration of response (DoR), time to objective response, and treatment-related adverse events (TRAEs).

Result

Among the patients, 122 (61.6%) received combination therapy as first-line treatment, while 76 (38.4%) as second-line or beyond. ORR was 58.6% (95% CI: 51.4–65.5), with a median PFS of 13.0 months; median OS was not reached. Subgroup analyses showed consistent ORR across all subgroups. Adverse events (AEs) occurred in 79.8% of patients, with grade 3–4 AEs in 19.7%. Common AEs included neuropathy (40.4%), fatigue (26.8%), alopecia (25.3%), and rash (21.7%). The main limitations of this study include its retrospective design and the population of the study only include patients from China, leading to potential selection bias.

Conclusions

RC48-ADC combined with ICIs demonstrated robust antitumor activity and a favorable safety profile in real-world mUTUC, particularly in selected patient groups. Further studies are needed to explore its potential in this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellImmune Checkpoint InhibitorsOligopeptidesUrologic NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

Disitamab vedotinImmune checkpoint inhibitorsImmunotherapyTargeted therapyUpper tract urothelial carcinoma

Substanzen

Antibodies, Monoclonaldisitamab vedotinImmune Checkpoint InhibitorsOligopeptides

Autor:innen und Institutionen

  • Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
  • The First Affiliated Hospital, School of Medcine, Zhejiang University, #79 Qingchun Rd., Hangzhou, 310003, Zhejiang Province, People's Republic of China.
  • Department of Urology, Sir Run Run Shaw Hospital, School of Medicine Zhejiang University, No.3 East Qingchun Road, Hangzhou, People's Republic of China.
  • Department of Urology, West China Hospital Sichuan University, Chengdu, 610041, China.
  • Department of Urology, Affiliated Drum Tower Hospital Medical School of Nanjing University, Nanjing, People's Republic of China.
  • The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, China.

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Municipal Health Commission
  • Beijing Xisike Clinical Oncology Research Foundation
  • National Natural Science Foundation of China
  • Wu Jieping Medical Foundation

Zitieren

APA

Ng, C., Jing, T., Yu, S., Ye, J., Zhang, S., Jia, Z., Tang, Q., Hu, X., Chen, M., Huang, W., Wu, J., Bi, H., Yan, Z., Shen, H., Xiong, W., Liu, Z., Xiao, J., Zhang, T., Wei, X., …, & Huang, J. (2025). The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04154-5

Vancouver

Ng C, Jing T, Yu S, Ye J, Zhang S, Jia Z, et al. The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04154-5

BibTeX
@article{Ng2025,
  author = {Ng, Cheoklong and Jing, Taile and Yu, Shicheng and Ye, Jianjun and Zhang, Shun and Jia, Zhankui and Tang, Qi and Hu, Xiaoyi and Chen, Minfeng and Huang, Weiping and Wu, Jitao and Bi, Hai and Yan, Zejun and Shen, Haibo and Xiong, Wei and Liu, Zheng and Xiao, Jun and Zhang, Tao and Wei, Xuedong and Hu, Hailong and Yang, Qing and Yuan, Yichu and Huang, Zhiyang and Xue, Wei and Bao, Yige and Ding, Guoqing and Xia, Dan and Huang, Jiwei},
  title = {The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04154-5}
}
Kostenlos starten →